Credit Suisse Ag Halozyme Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 201,642 shares of HALO stock, worth $10.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

201,642

Previous 203,773 1.05%

Holding current value

$10.3 Million

Previous $7.53 Million 8.91%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$33.68 - $41.95 $71,772 - $89,395	-2,131 Reduced 1.05%	201,642 $8.2 Million
Q4 2023 Feb 08, 2024	SELL	$33.32 - $42.1 $119,085 - $150,465	-3,574 Reduced 1.72%	203,773 $7.53 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $702,657 - $848,546	-19,272 Reduced 8.5%	207,347 $7.92 Million
Q2 2023 Aug 11, 2023	BUY	$30.28 - $38.74 $1.47 Million - $1.88 Million	48,436 Added 27.18%	226,619 $8.17 Million
Q1 2023 May 10, 2023	BUY	$32.86 - $55.7 $132,688 - $224,916	4,038 Added 2.32%	178,183 $6.8 Million

Q4 2022 Feb 13, 2023	BUY	$40.06 - $59.44 $147,581 - $218,976	3,684 Added 2.16%	174,145 $9.91 Million
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $180,397 - $242,433	4,682 Added 2.82%	170,461 $6.74 Million
Q2 2022 Aug 12, 2022	SELL	$37.35 - $48.3 $114,776 - $148,425	-3,073 Reduced 1.82%	165,779 $7.29 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $25,991 - $33,381	813 Added 0.48%	168,852 $6.73 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $225,890 - $289,284	-7,099 Reduced 4.05%	168,039 $6.76 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $941,822 - $1.14 Million	24,482 Added 16.25%	175,138 $7.13 Million
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $189,383 - $250,187	-4,876 Reduced 3.14%	150,656 $6.84 Million
Q1 2021 May 14, 2021	SELL	$39.51 - $51.45 $4.12 Million - $5.37 Million	-104,386 Reduced 40.16%	155,532 $6.48 Million
Q4 2020 Feb 12, 2021	BUY	$25.81 - $43.62 $2.48 Million - $4.19 Million	96,066 Added 58.63%	259,918 $11.1 Million
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $1.63 Million - $1.87 Million	-63,178 Reduced 27.83%	163,852 $4.31 Million
Q2 2020 Aug 12, 2020	BUY	$16.25 - $26.81 $2.1 Million - $3.47 Million	129,379 Added 132.49%	227,030 $6.09 Million
Q1 2020 May 13, 2020	SELL	$13.9 - $21.83 $1.12 Million - $1.75 Million	-80,336 Reduced 45.14%	97,651 $1.76 Million
Q4 2019 Feb 12, 2020	BUY	$14.93 - $19.53 $445,272 - $582,462	29,824 Added 20.13%	177,987 $3.16 Million
Q3 2019 Nov 12, 2019	SELL	$15.2 - $17.69 $1.19 Million - $1.39 Million	-78,335 Reduced 34.59%	148,163 $2.3 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $348,468 - $407,767	23,625 Added 11.65%	226,498 $3.89 Million
Q1 2019 May 14, 2019	BUY	$13.94 - $17.58 $644,139 - $812,336	46,208 Added 29.49%	202,873 $3.27 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $804,798 - $1.13 Million	60,375 Added 62.7%	156,665 $2.29 Million
Q3 2018 Nov 13, 2018	SELL	$16.68 - $18.41 $242,510 - $267,662	-14,539 Reduced 13.12%	96,290 $1.75 Million
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $679,793 - $818,008	-40,296 Reduced 26.66%	110,829 $1.87 Million
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $466,642 - $579,883	27,353 Added 22.1%	151,125 $2.96 Million
Q4 2017 Feb 14, 2018	SELL	$16.75 - $20.8 $2.54 Million - $3.16 Million	-151,686 Reduced 55.07%	123,772 $2.51 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $340,393 - $503,642	28,945 Added 11.74%	275,458 $4.78 Million
Q2 2017 Aug 14, 2017	BUY	N/A	246,513	246,513 $3.16 Million

Others Institutions Holding HALO

# of Institutions

441

Shares Held

122M

Call Options Held

216K

Put Options Held

140K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.15B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account